BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer. 2011;105:1203-1209. [PMID: 21934681 DOI: 10.1038/bjc.2011.347] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Arcaro KF, Browne EP, Qin W, Zhang K, Anderton DL, Sauter ER. Differential expression of cancer-related proteins in paired breast milk samples from women with breast cancer. J Hum Lact 2012;28:543-6. [PMID: 22914689 DOI: 10.1177/0890334412453205] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
2 Wang X, Cai C, Xu J, Jin H, Xu Z. Increased expression of chitinase 3-like 1 is a prognosis marker for non-small cell lung cancer correlated with tumor angiogenesis. Tumor Biol 2015;36:901-7. [DOI: 10.1007/s13277-014-2690-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
3 Fuksiewicz M, Kotowicz B, Rutkowski A, Achinger-Kawecka J, Wagrodzki M, Kowalska MM. The Assessment of Clinical Usage and Prognostic Value of YKL-40 Serum Levels in Patients With Rectal Cancer Without Distant Metastasis. Technol Cancer Res Treat 2018;17:1533033818765209. [PMID: 29642772 DOI: 10.1177/1533033818765209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Zheng X, Xing S, Liu XM, Liu W, Liu D, Chi PD, Chen H, Dai SQ, Zhong Q, Zeng MS. Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma. BMC Cancer. 2014;14:490. [PMID: 25001061 DOI: 10.1186/1471-2407-14-490] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
5 Willemsen AECAB, Tol J, van Erp NP, Jonker MA, de Boer M, Meek B, de Jong PC, van Moorsel C, Gerritsen WR, Grutters JC, van Herpen CML. Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. Target Oncol 2019;14:441-51. [PMID: 31325105 DOI: 10.1007/s11523-019-00656-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 2014;5:75. [PMID: 24634660 DOI: 10.3389/fphys.2014.00075] [Cited by in Crossref: 244] [Cited by in F6Publishing: 263] [Article Influence: 30.5] [Reference Citation Analysis]
7 Wang D, Zhai B, Hu F, Liu C, Zhao J, Xu J. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One 2012;7:e51127. [PMID: 23227243 DOI: 10.1371/journal.pone.0051127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
8 Ma B, Herzog EL, Moore M, Lee CM, Na SH, Lee CG, Elias JA. RIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary Metastasis. Sci Rep 2016;6:26299. [PMID: 27198666 DOI: 10.1038/srep26299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
9 Kzhyshkowska J, Larionova I, Liu T. YKL-39 as a Potential New Target for Anti-Angiogenic Therapy in Cancer. Front Immunol 2019;10:2930. [PMID: 32038607 DOI: 10.3389/fimmu.2019.02930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Elmonem MA, van den Heuvel LP, Levtchenko EN. Immunomodulatory Effects of Chitotriosidase Enzyme. Enzyme Res 2016;2016:2682680. [PMID: 26881065 DOI: 10.1155/2016/2682680] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
11 Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol 2013;4:122. [PMID: 23755018 DOI: 10.3389/fphys.2013.00122] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
12 Ma B, Akosman B, Kamle S, Lee CM, He CH, Koo JS, Lee CG, Elias JA. CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses. J Clin Invest 2021;131:e137750. [PMID: 34720089 DOI: 10.1172/JCI137750] [Reference Citation Analysis]
13 Wan G, Xiang L, Sun X, Wang X, Li H, Ge W, Cao F. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients. Oncotarget 2017;8:5382-91. [PMID: 28036271 DOI: 10.18632/oncotarget.14280] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
14 Yasar O, Akcay T, Obek C, Turegun FA. Diagnostic potential of YKL-40 in bladder cancer. Urologic Oncology: Seminars and Original Investigations 2016;34:257.e19-24. [DOI: 10.1016/j.urolonc.2016.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Xing S, Zheng X, Zeng T, Zeng MS, Zhong Q, Cao YS, Pan KL, Wei C, Hou F, Liu WL. Chitinase 3-like 1 secreted by peritumoral macrophages in esophageal squamous cell carcinoma is a favorable prognostic factor for survival. World J Gastroenterol 2017; 23(43): 7693-7704 [PMID: 29209110 DOI: 10.3748/wjg.v23.i43.7693] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
16 Xavier CPR, Castro I, Caires HR, Ferreira D, Cavadas B, Pereira L, Santos LL, Oliveira MJ, Vasconcelos MH. Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine. Cancer Lett 2021;501:210-23. [PMID: 33212158 DOI: 10.1016/j.canlet.2020.11.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
17 Libreros S, Garcia-Areas R, Iragavarapu-Charyulu V. CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol Res. 2013;57:99-105. [PMID: 24222276 DOI: 10.1007/s12026-013-8459-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
18 Williams MM, Hafeez SA, Christenson JL, O'Neill KI, Hammond NG, Richer JK. Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways. Pharmaceuticals (Basel) 2021;14:1122. [PMID: 34832904 DOI: 10.3390/ph14111122] [Reference Citation Analysis]
19 Hamilton G, Rath B, Burghuber O. Chitinase-3-like-1/YKL-40 as marker of circulating tumor cells. Transl Lung Cancer Res 2015;4:287-91. [PMID: 26207216 DOI: 10.3978/j.issn.2218-6751.2015.04.04] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
20 Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 Like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5:201. [PMID: 32929074 DOI: 10.1038/s41392-020-00303-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
21 Huang WS, Lin H, Yeh C, Chen L, Chou Y, Yang S, Liu Y. Correlation of Chitinase 3-Like 1 Single Nucleotide Polymorphisms with Hepatocellular Carcinoma in Taiwan. Int J Med Sci 2017;14:136-42. [DOI: 10.7150/ijms.17754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
22 Morera E, Steinhäuser SS, Budkova Z, Ingthorsson S, Kricker J, Krueger A, Traustadottir GA, Gudjonsson T. YKL-40/CHI3L1 facilitates migration and invasion in HER2 overexpressing breast epithelial progenitor cells and generates a niche for capillary-like network formation. In Vitro Cell Dev Biol Anim 2019;55:838-53. [PMID: 31482369 DOI: 10.1007/s11626-019-00403-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Shahy EM, Taha MM, Ibrahim KS. Assessment of YKL-40, lipid profile, antioxidant status, and some trace elements in benign and malignant breast proliferation. Mol Biol Rep 2020;47:6973-82. [PMID: 32876843 DOI: 10.1007/s11033-020-05756-1] [Reference Citation Analysis]
24 Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol 2014;35:277-86. [PMID: 23918300 DOI: 10.1007/s13277-013-1036-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
25 Bian B, Li L, Yang J, Liu Y, Xie G, Zheng Y, Zeng L, Zeng J, Shen L. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Cancer Cell Int 2019;19:259. [PMID: 31624472 DOI: 10.1186/s12935-019-0983-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
26 Chen HY, Zhou ZY, Luo YL, Luo Q, Fan JT. Knockdown of YKL-40 inhibits angiogenesis through regulation of VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancer. Cell Biol Int 2021. [PMID: 34498339 DOI: 10.1002/cbin.11699] [Reference Citation Analysis]
27 Oh IH, Pyo JS, Son BK. Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer. Curr Oncol 2021;28:3139-49. [PMID: 34436040 DOI: 10.3390/curroncol28040274] [Reference Citation Analysis]
28 Yeo IJ, Lee CK, Han SB, Yun J, Hong JT. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther 2019;203:107394. [PMID: 31356910 DOI: 10.1016/j.pharmthera.2019.107394] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
29 Shaker OG, Senousy MA. Association of SNP-SNP Interactions Between RANKL, OPG, CHI3L1, and VDR Genes With Breast Cancer Risk in Egyptian Women. Clin Breast Cancer 2019;19:e220-38. [PMID: 30309792 DOI: 10.1016/j.clbc.2018.09.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
30 Zhang JP, Yuan HX, Kong WT, Liu Y, Lin ZM, Wangs WP, Guo JM. Increased expression of Chitinase 3-like 1 and microvessel density predicts metastasis and poor prognosis in clear cell renal cell carcinoma. Tumour Biol 2014;35:12131-7. [PMID: 25142236 DOI: 10.1007/s13277-014-2518-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
31 Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol 2014;31:85. [PMID: 24996799 DOI: 10.1007/s12032-014-0085-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
32 Xu Q, Chai SJ, Qian YY, Zhang M, Wang K. Breast regression protein-39 (BRP-39) promotes dendritic cell maturation in vitro and enhances Th2 inflammation in murine model of asthma. Acta Pharmacol Sin 2012;33:1525-32. [PMID: 23178461 DOI: 10.1038/aps.2012.154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
33 Pan JJ, Ge YS, Xu GL, Jia WD, Liu WF, Li JS, Liu WB. The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2013;139:1043-1054. [PMID: 23525579 DOI: 10.1007/s00432-013-1415-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
34 Luo D, Chen H, Lu P, Li X, Long M, Peng X, Huang M, Huang K, Lin S, Tan L, Zhu Y, Chen Z, Ouyang N, Li H. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma. Cancer Biomark 2017;18:273-84. [PMID: 28009325 DOI: 10.3233/CBM-160255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
35 Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T. Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. J Urol 2016;195:1120-5. [PMID: 26454102 DOI: 10.1016/j.juro.2015.09.084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
36 Hamilton G, Rath B, Ulsperger E. How to target small cell lung cancer. Oncoscience 2015;2:684-92. [PMID: 26425658 DOI: 10.18632/oncoscience.212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
37 Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, San Martín-Paniello C, Clarimon J, Belbin O, Fortea J, Lleó A. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. J Neuroinflammation 2017;14:118. [PMID: 28599675 DOI: 10.1186/s12974-017-0893-7] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 12.0] [Reference Citation Analysis]
38 Qin R, Liao M, Qin W, Wang J, Zheng F, Ma N, Zhao Y, Qin A. The Diagnostic value of Serum YKL-40 in Endometrial Cancer: a meta-analysis. Biomarkers 2022;:1-14. [PMID: 34974784 DOI: 10.1080/1354750X.2021.2024603] [Reference Citation Analysis]
39 Liu T, Larionova I, Litviakov N, Riabov V, Zavyalova M, Tsyganov M, Buldakov M, Song B, Moganti K, Kazantseva P, Slonimskaya E, Kremmer E, Flatley A, Klüter H, Cherdyntseva N, Kzhyshkowska J. Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy. Oncoimmunology 2018;7:e1436922. [PMID: 29872578 DOI: 10.1080/2162402X.2018.1436922] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
40 Chen H, Zheng J, Zhang Y, Yang M, Wang Y, Man X, Chen Y, Cai Q, Li Z. Overexpression of YKL-40 Predicts Poor Prognosis in Patients Undergoing Curative Resection of Pancreatic Cancer. Pancreas 2017;46:323-34. [DOI: 10.1097/mpa.0000000000000751] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]